Showing results (561-570 of 627) with videos related to
Sort By:
Pageof 63
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.Clinical Trials (London, England)|April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challengesThomas R Fleming, David L DeMets, Matthew T Roe, et al.Journal of the American Heart Association|October 30, 2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AFJeffrey B Washam, DaJuanicia N Holmes, Laine E Thomas, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.American Heart Journal|May 27, 2019
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation IITaku Inohara, Peter Shrader, Karen Pieper, et al.Heart (British Cardiac Society)|January 9, 2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillationTaku Inohara, DaJuanicia N Holmes, Karen Pieper, et al.Pageof 63